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INTRODUCTION A (C.!.A ') 
With the introduction of Cyclosporinel into clinical transplantation, 
survival rates for patient and grafts have improved dramatically. 
Nevertheless, allograft rejection and the consequences of treatment of 
rejection continues to be the most common cause of retransplantation and 
death. Clinical rejection occurs in up to 80% of solid organ allograft 
CsA 
recipients, who are maintained on UyU1Us~er>ir:l9 and steroid therapy. In 
addition, a number of toxicities, including nephrotoxicity may limit the 
C.5A. 
optimal use of eysles,:leriA&. Chronic renal damage and functional 
impairment has been shown to occur in transplant patients, and 
hypertension, requiring antihypertensive therapy, occurs in the majority 
of these patients. Alterations in clinical immunosuppression to prevent 
or reverse these and other side effects have included: 1) reduction of (sA 
oyslg.porir:l9 dose or 2) addition of azathoprine, antilymphocyte 
antibodies, or other agents with concomitant reductions in the 
CsA 
o;'elesJ3eptAe dose. These methodologies have their inherent dangers; 
increasing susceptibility to rejection and increased susceptibility to 
i ntection, respectively. 
FK506 is a potent and novel immunosuppressive agent, discovered in 
Japan less than l years ago (1-3). A detailed summary of _the preclinical 
at FK5'Ob AK~gKK y~ ,1""fwl'S )., 1" aK~ ~ o~ ,IAi£ VO"JMe. 
development,Ahas been published in monograph form (4-61 The purpose of 
this chapter is to summarize the experience of FK506 in solid organ 
transplantation at a single center. with appropriate notation of results at 
FK506 experiences. as reported in the literature. 
2. 
LIVER RESCUE THERAPY ~ ;-~ rtyK~t~itr cf fdh.b"f'W\ MtK~tg (eV\\et ) ~ c (OrMc..) • 
A Phase 1111 trial of FK506 was initiated in 1989 (as the first use of 
FK506. The indication for FK506 therapy was in patients who were 
rejecting their 
immunosuppression. 
doses of FK506 with 
liver allografts, in spite of conventional 
The protocol was initially designed to combine low 
C:.A. 
s¥c'c;r;;;FiRe. This combination was attempted in the 
first eleven patients, but was accompanied by a number of adverse 
reactions. Eventually, a simple switch (clean conversion) was made from 
C~A 
eyelo3"eri"e to FK506 (7). 
All patients had an initial entry diagnosis of uncontrolled liver 
C~AKg 
allograft rejection andlor other complications related to c¥Qlg;pgrige, i.e. 
renal dysfunction or hypertension. These patients were therefore 
considered treatment failures of conventional immunosuppression. Prior 
to conversion to FK506, maintenance immunosuppression in all patients 
Cs.A 
was with cyelesr;;FiFl9 and prednisone, with or without azathioprine. 
CsA 
~ospeDioe doses had been maximized to tolerable levels, as limited by 
renal dysfunction or hypertension. o~ FI<.SOb 
The results of this study showed a marked ability~ to reverse ongoing 
rejection, even in cases where chronic changes were observed (7,8). 
These results have subsequently been verified by a number of 
o'the.r ~Kt~I bo-t~ ,'W\ -tNt Un·.tld.. S'hdu w b~"IpeK 
iFlf8FAat+eRai eRg AcAer~aA eFE~ci9AneC/E9-1PFK In this high risk group of 
bf- w~owy h~ A 
patients, many}.. WAg R8ve received azathioprine, OKT3 and high doses of 
steroids, a beneficial effect of FK506 was not originally expected to be a 
major one. Yet. over 70% of patients treated by conversion to FK506 had 
both clinical and histopathologic responses. Marked improvement in 
biochemical parameters were noted in a majority of patients. Those 
patients who did not respond to FK506 conversion. had histopathologic 
evidence of end stage chronic rejection, with obliteration of vascular 
lumen, and total disappearance of intrahepatic bile duct structures. 
Nevertheless, a number of patients, with marked liver function 
abnormalities, responded by returning to normal levels. 
The United States Multi-center FK506 Liver Study Group recently 
prognostic factors for successful conversion from analyzed the 
C.s.A-
ayelea"eriPle- to FK506 -based immunosuppressive therapy for refractory 
1DyynKrMAcKwh~ <4., U-J.. • .) 
rejection (Fujisawat personal communication). A total of 125 patients 
were studied. The median time to FK506 conversion from transplantation 
peDl~iy -tht-te. 
was 143 days (range 13 to 3269 days). I~ patients were treated for 
refractory acute rejection, 44 for chronic rejection and 6 for both. Two 
patients had unknown causes for liver allograft dysfunction. At one month 
ha.! 
after conversion, 54% of patients were noted to have, complete or partial 
,. -h h~~eKK 1\ 
responsi1 or/cliniCally improved. By 6 months after conversion, this 
benefit was noted in 67% of patients, and 86% at one year. The one year 
actuarial graft and patient survival after FK506 conversion was 50% and 
72%, respectively. Multivariate analysis of risk factors showed that the 
following were adversely related to graft survival: elevated total 
bilirubin and serum transaminases, as well as prevIous liver 
transplantation. Patients with a total serum bilirubin of 13 mg/dl had a 
r ~ ~ 
5.1 tim~;y greater risk of graft failure andl3.1 tim~ greater risk of death as 
compared to those with a serum bilirubin of 2 mg/dl or lower. Similarly, 
f"\ 
those with a baseline SGOT of 300 lUlL had a 2.5 timi greater risk of 
graft failure than those With a SGOT of 80 lUlL or lower, but were not at a 
higher risk of dying. The mean Kornofsky score was 58 pre-conversion and 
85 at 6 and 12 months after FK506 conversion. 
PRIMARY LIVER TRANSPLANTATION 
;(.A.. 
An initial primary treatment study was 
U¥Mt. • poKKt·t~t1 
UAiversity af mitt!e~fD~MK qhes~1 were the first 
Ir" 
begIn in August 1989, at the 
SUDJU.'t\ 
human r;atiQr;lts to be given 
FKS06, along with low dose steroids, as their primary immunosuppressive 
baseline regimen (14). FKS06 was shown to be remarkably potent and 
successful as primary immunosuppression; in liver transplantation. In the 
4.. 
initial series of patients'Atotal of 92 (92.7%) of the 110 FKS06 primarily 
treated liver transplant patients were alive between 6 and 12 months 
_--:--___ -,. fltoJe. (1S). These results were J-statisticallyl better) than ~ of the 32S 
CsA 
It\ tNt. €Ieles~erioUK treated control group. The rate of retransplantation was 
in C.!.A 
over one half less than the retransplant rate seen ~ the syGIQs,aQriR& 
control group. In these studies, 3 broad areas of toxicity were noted: 
nephrotoxicity, neurotoxicity, and alterations in carbohydrate metabolism. 
Our initial impression was that FKS06 was as effective as 
C~A ) 
cyclosporjoe. J although the overall risk/benefit ratio required further 
study. A randomized trial was performed to compare FKS06 with 
C.J.A 
oyclosPQrir;lQ (16,17). The design of this study was to use FK506 and 
C~AF 
nyU1Up~nrfmnI along with steroids, in a randomized fashion, in patients 
undergOing primary liver transplantation. The primary endpoint was the 
failure of the defined treatment to prevent and control rejection. Our 
presumption was that graft and patient survival would be essentially the 
same between the two treatment groups because patient outcome after 
treatment failure would be individualized to each patient as deemed 
necessary by the Investigator. Therefore patient and graft survival was 
conSIdered only as a secondary endpoint. The rejection free ratel was 
chosen as the primary endpoint in order to provide sufficient objective 
4-
~K-~---K--
evidence to resolve the key question of efficacy of either FK506 or 
("rA • 
cyclo;pgrir.409. 
Cs.A 
Two sequential phases of the randomized trial were constructed. 
~ and FK506 were given in the same manner in both phases, the only 
C5A 
differences being the steroid dosing for the _yclo;pgriR8 arm. In "Phase 
1", a rejection episode was treated with a single bolus of one gram of 
methylprednisolone. 
CJ.A 
In "Phase 2", augmented steroid therapy was given to 
ColA 
the "yclospocine arm in attempts to normalize the 4iiyU19C~9cioU therapy 
with other multicenter protocols. In both phases, if this treatment failed 
to reverse the rejection episode, then further treatment was 
individualized. In both phases, the FK506 arm was kept on the same doses 
of steroids. Thus the FK506 arm with low dose steroids (LOS) was 
CJ.A 
compared to two different cy£lo;pori~e regimens, one with LOS and the 
other with standard steroid therapy (SST). The primary endpoint was to 
examine the incidence of rejection following liver tran~lantationI and to 
compare graft and patient survival in FK506 with LOS, d~ with LOS, and 
Col A 
~ with SST. One hundred fifty four (154) patients were enrolled 
between February 17,1990 and December 30, 1991. LOS therapy consisted 
of one gram of methylprednisolone (MP), while SST consisted of a gram of 
MP followed by a six day steroid taper, for both induction and treatment of 
-ilK~leK 1 rejection. The patient demographics and results are shown in Table 1. 
The one year patIent and graft survival. as analyzed by intent to treat, 
was 92% and 88% respectively for FK506, compared to 85% and 79% 
{.sA 
respectively for eyelesB9flR8. The freedom from reJection was 
statIstically greater in the FK506 - treated group, as compared to 
C1A, -
cyelespeflAo treated groue. 
Cs. A) 
A total of 53 (70%) of patients who were on 'd;A, were converted to 
FK506 with LOS immunosuppression, 43 patients because of recurrent or 
refractory rejection after steroid treatment for rejection, 5 patients for 
preservation injury, 2 patients following retransplantation, 1 patient for 
Rh incompatibility, and 1 patient drop out. Only one patient on FK506 was 
{.sA. 
converted to~K Of the patients who were converted to FK506, 22 (420/0) 
of patients are on FK506 only (no steroids), as compared to 41 % of 
patients who were randomized to the FK506 limb initially. 
The results in this single center study have been compared to two 
other ongoing randomized liver transplant trials In both the United States 
and Europe (Fujisawa, personal communication). In each series, over 500 
patients were entered into the combined limbs. Using a regimented FK506 
treatment arm, the results obtained in the early preliminary results 
support the findings at the University of Pittsburgh. The European study 
demonstrated a 15% enhanced patient and graft survival in the FK506 
C~AK 
limb, when compared to the ~ limb. Although the patient survival was 
similar in both groups in the American study, there was a slight benefit in 
graft survival in the FK506 limb. In both studies, there was less rejection 
in the FK506 limb, and the overall dosing of steroids was less in the 
FK506 limb. The results of these studies are still being analyzed and will 
be officially reported later this year/ Ef~q~FK 
KIDNEY RESCUE TRIALS 
The application of FK506 rescue therapy to kidney transplantation 
was an extension of the experience gained in liver transplantation. The 
predominant difference between the two organ systems IS the 
predomrnance of arteriopathy and sclerosis of epithelial structures in the 
kidney allografts undergoing chronic rejection. This was found to limit 
the ability of FK506 to rescue grafts with this pathologic finding. In a 
series of 35 patients, those with ongoing acute cellular rejection had a 
successful conversion rate of 71 %, while those with stigmata of chronic 
rejection were not able to be rescued (18). Those with living related 
kidney transplants had a higher rate of rescue (73%) as compared to those 
with cadaveric grafts (50%), probably related to an earlier referral for 
FK506 rescue therapy. 
PRIMARY KIDNEY TRANSPLANTATION 
FK506 has been utilized as primary baseline immunosuppression in 
two series of patients. Shapiro and coworkers (19) reported on a series of 
234 patients undergoing kidney transplantation with FK506, and compared 
the results to a concurrent single institution experience with 
Csf.... 
C¥SIOSpSFiAC. The patient characteristics and results of the study are 
-l.hle. 'L shown in Table 2. While the immunologic characteristics of the FK506 
E~A 
group was less favorable as compared to the ~DCfnq?ncfos limb, the 
results of graft survival and graft function were no different. 
Nevertheless, the incidence of hypertension and freedom from steroid use 
was statistically better with the use of FK506, confirming the previous 
findings with the primary liver transplant experience. 
A multicenter study of primary kidney transplantation under FK506 
was reported by the Japanese FK506 study group in 1991 (20). In this 
pilot Japanese experience. 37 kidney transplant patients were given 
FK506 at fixed doses, and the drug levels correlated with side effects at 
Fo",r., ('\)( ~I (er\'t . . . . 
the conclusion of the study. J... ~ at the patients experienced a rejection 
episoae, however the maJority of patients (84%) were living related 
transplants. The three month survival for both grafts and patients was 
100%. Toxicity consisted of renal impairment, gastrointestinal 
complaints. hyperkalemia, tremor, hyperglycemia and chest discomfort. 
and was associated with a FK506 whole blood level greater than 20 ng/ml. 
A randomized trial. utilizing FK506 in a double drug regimen (FK506 
and steroids) versus a triple drug regimen (FK506. steroids and 
azathioprine), was performed in kidney transplantation at the University 
T .... , nuV\W o.I\A four 
of Pittsburgh (Shapiro R et al. manuscript in preparation). ff!!iJ+ patients 
were enrolled; there were no specific exclusion criteria based on 
qhy~tKKI p~ED ce.nt" 
immunologic or transplant history. 1. ~ of the patients were undergoing a 
retransplant, with 17% of the recipients being sensitized (PAA>40%). The 
~ 
one year actuarial patient and graft survivax for the two drug-versus three 
drug-regimen were: 95% and 900/0 versus 91% and 820/0. respectively. No 
differences were noted in __ kidney functio~ with the mean serum 
creatinine of 1.8 ±. 0.8 mg/dl. The rejection rate in the three drug regimen 
was less than that for the two drug regimen (37% vs. 51 0/0 ), although this 
was not statistically significant (p=0.07). Crossover from one group to 
another was not uncommon, 25% of the two drug group were given 
azathioprine, principally due to rejection, while 45% of the three drug 
group required discontinuation of azathioprine because of leucopenia or 
hepatic dysfunction. 
HEART TRANSPLANTATION UPM'-. 
ArmItage and coworkers at thef-lJ Ii Wi b~ af I'l#tsUmgh have 
reported their experience with FK506- based immunosuppression following 
heart transplantatIon (21,22). In 8 patients. FK506 was utilized as 
rescue therapy for patIents suffenng from persistent. refractory cardiac 
C~A 
rejection on cYGteSJ30riAo, azathioprine and steroids (21). All of these 8 
patients had received and failed one or more courses of antilymphocyte 
C:,./\ 
therapy while of cyeto9j3sriFlO therapy. In keeping with the previous 
experiences with rescue therapy, all of these patients had demonstrated 
improvement in the histopathology after FK506 conversion. 
SeVt'l\t, two 
~ I primary adult patients were given FK506 as primary 
immunosuppression following heart transplantation (22). The one year 
patient and graft survival was 920/0 (Figure 1). The overall rejection rate 
was 67%, with 33% of these patients not having any rejection. The 
freedom from rejection at 90 days was 41 % and at 180 days was 34%. 
Renal dysfunction was frequently noted, and the mean serum creatinine at 
6 months following transplantation was 2.2 mg/dl. The incidence of 
diastolic hypertension was 54%, but was considered mild, as treatment 
consisted of a single agent in all cases. The incidence of new onset 
diabetes was 20% in this group of patients. 
INTESTINAL TRANSPLANTATION 
One way to assess the impact of a new immunosuppressive agent in 
transplantation, is the ability to successfully transplant organs, which 
were not considered feaSible with standard immunosuppression. This was 
C5A 
certainty the situation when "),818!J!eri...e was introduced to liver 
transplantation (23). Success with intestinal transplantation under 
o€y"jnf~t:iog immunosuppression has been sporadic (24-26). 
A growing experience of small bowel transplantation, either alone. 
or combined with other abdominal organs. has been accumulated under 
UPMC. 
FK506 at the JJAi'i'@rJ([y Of Pittsgwrgb (27-30). Small bowel allografts 
have been transplanted alone (n=9), together With liver (n=16), or as part 
of a multivisceral cluster (n=3). In these 28 patients. 820/0 were alive at a 
median followup of 9 months. Graft survival was 76% at the same period . 
So hKo~ .. \" 
of time. Graft function was satisfactory) with 84% of survivors beiAfj ~ 
;-:t;~!n~ ""'f ~ enteralW sufficient and the other 16% relying on supplemental 
parenteral nutrition. Rejection was not uncommon) with 90% of the 
patients having at least one rejection episode of the intestinal allograft. 
Rejection has been treated by additional steroids and addition of 
azathioprine; however) anti-lymphocyte preparations have been used 
occasio nally. 
LUNG TRANSPLANTATION 
A small experience of pediatric lung transplantation under FK506 
has been reported by Armitage and coworkers (31). Eleven patients 
received FK506, two of whom have died because of early infectious 
complications. While rejection episodes were no different between FK506 
C~A ) CIA 
and cyeissJ:)8rifle. unlike the cjDcfnK~eci~ experience, antilymphocyte 
preparations have not been required to reverse rejections on FK506. In 
addition, hypertension was not seen in the FK506 group, as compared to an 
C.s.A 
incidence of 50% in the cj'.leSJ38FiR8 group. 
A prospective randomized trial of primary adult pulmonary 
UPMC-
transplantation was conducted at the UPli, erellt)' ef mitt!ll!~f~" (Griffith BP 
et al. manuscript in preparation). Azathioprine was combined with either 
C~AKI 
FK506 or cyr;19K~icfo9DI resorting to using steroids only if the recipient 
T'NeV\11 t", .. ht 
encountered more than a ne episode of reJection. iJii/ patients were 
A.. [.sA. 
randomized to FK506: 29 patients were randomized to ,cYCIQiJ&lQr'OQ. The 
six month oraft survival was statistically better in the FK506 group as 
-. Cs.A 
comparea to the eyeie!r;ol Ii Ie grouc (86% vs. 69% respectively, p<O.05). 
to 
q~f~1 lry~ ~ cewtt 
~of the FK506 patients were rejection free at 6 months, as compared 
A CsA 
to only 3% of the eyglgsfiiiFiR9 patients. 
OTHER FK506 ISSUES 
The results of these studies suggest that FK506 is effective for 
solid organ transplantation. The dosing schedule and monitoring 
techniques for FK506 continue to be modified. One of the principle issues 
regarding the use of FK506 has been with monitoring of drug levels. In 
Europe and at other centers in the United States, whole blood levels have 
been utilized. This measures not only plasma levels (the assay utilized at 
our institution), but also cell-bound FK506. The principle advantage of 
whole blood levels are the higher FK506 levels which can be detected, 
making adjustments in FK506 dosing potentially easier. In addition, whole 
blood monitoring offers the advantage of faster analysis times and less 
variability of sample storage and preparation disparity. We are currently 
measuring both whole blood levels and plasma levels in order to gain 
clinical experience utilizing FK506 whole blood monitoring. 
DISCUSSION 
While impressive gains in patient and graft survival have been 
obtained in solid organ transplantation, rejection continues to play a 
significant role In morbidity and mortality. A search for new 
immunosuppressive agents must be able to impact on the rates and 
seventy of rejection. Ample clinical reports correlate the adverse impact 
ot rejection on long term gratt survival. In the clinical trials presented 
here. FK506 appears to provide a baseline immunosuppression which is 
h Cs A , .. h" ltd 'th potent t a~ ~jD~fn .. gnt~nK At our Institution, t IS IS corre a e WI 
-fW o..th·'f Vfa w', ih 
more 
II 
enhanced patient and graft survival at one year. In addition, the impact of 
FK506 on previously "forbidden" transplantation, has been dramatic, with 
the introduction of a successful intestinal transplantation program and 
enhanced results ot lung transplantation. +~ 
We have reported encouraging clinical_ trials with (tit new 
immunosuppressive agent ifallee FK506, yg~i"" ii!/ a macrolide antibiotic 
;... E~KlK 
produced by the fungus, Streptomyces tsukubaensis". The molecular 
t+\.:t o~ ''''''1 
structure of FK506 is unrelated to ~ eyelee~ecfm~eI and the 2 drugs have 
(32, p~FK 
different cytoso/ic binding site:t~~Ej;t;Ej~K~~D~*IK However, both drugs inhibit T-
lymphocyte activation, in part by suppressing the synthesis and 
(3lt,3S). 
expression of the cytokine, inter/eukin-2 E~RIaUFK Yet there is a practical 
difference in the utilization of these agents. The ability of FK506 to be 
used to reverse ongoing, established rejection, is not a characteristic of 
C~A . 
-9yDfnK~nrineK The dose adjustability of FK506 allows the physician to 
titrate the immunosuppressive baseline to the threshold of rejection, 
rather than to J aroitrarlly' rely Ion target drug levels, which may represent 
overimmunosuppression for some, and underimmunosuppression for others. 
FK506 is not without its limitations. Toxicity profiles for FK506 
-tho~ C.sA ) 
are similar to ~ of Cvblf9S~grll:1nI perhaps because of simi/iar 
mechanisms of action. A detailed analysis and review of the adverse 
effects of FK506 is beyond the scope of this discourse. Readers are 
l-1iIa~~F . referred to detailed reports of FK506 adverse effects . 80th FK506 
C.sA ha..!. 
and -GysIS5J30rifte administration ~ been associated with Side effects. 
many of which are similar. and some of which are peculiar to a given 
organ transplant. 
A detailed analysis of all major adverse events was completed in 
( g~ ). 
370 consecutive prrmary liver transplant recipients t=). The one year 
IL 
patient and graft survival in this series was 85% and 77% respectively. 
Pretransplant renal dysfunction was seen in 31 (9%) of patients, of which 
23 required preoperative hemodialysis. Early onset renal dysfunction was 
13 
defined as a rise in the serum creatinine to >3 mg/dl in the first 30 days -1-
_ - o~ ~ eVeNI/\ ... 
after transplant. This occurred in 40% of patients. hf wRies Hal'lwas < ~ --
ascribed to FK506 toxicity and the remainder to other coexistent factors. 
The incidence of patients requiring hemodialysis following liver 
transplantation was twice as high in the later group than in patients with 
only FK506 nephrotoxicity. Most of the patients with early post-
transplant renal dysfunction returned to normal levels within 30 days 
o~ tha.. 
..,. transplant~K The incidence of chronic renal failure (defined as a 
serum creatinine >2.0 mg/dl) at 12 months following transplant was 
20.5%. The incidence appeared stable after 6 months following transplant. 
The incidence of renal failure requiring chronic hemodialysis was 1.20/0 in 
this study. 
Long-term hyperkalemia was seen in 37% of patients treated with 
FK506 and was generally treated with potassium binding resins and 
potassium restricted diets. Addition of a synthetic mineralocorticoid. 
Florinef, relieved the hyperkalemia by increasing potassium excretion by 
the kidney. 
Alterations In glucose metabolism are the result of changes in 
peripheral sensitivity to insulin and/or changes in the response of the 
islet cells to hyperglycemia. The incidence of permanent new onset 
diabetes. i.e. those patients requiring insulin. was 11.2% in liver 
transplant patients. The long-term consequence ot insulin requirement in 
transplant patients. towaras the development of diabetiC complications IS 
not known. 
Rare but severe instances ,of neurotoxicity have been reported 
""qfylr~ oV\Q. '-UfM.. 
following FK506 administration. 3=tL episodes of neurotoxicity 'W8S seen in 
the 370 liver transplant patient study. New onset seizures were reported 
in 12 liver transplant patients, especially during the perioperative 
transplant period (incidence of 3%). The susceptibility of such patients to 
changes in serum electrolytes has beenrpreviouslyl reported}1f Delirium was 
noted in 11 patients (incidence of 3%). Persistent coma was noted in 4 
patients (incidence of 1 %). Expressive aphasia has been seen in five liver 
transplant patients (1 % incidence). In all but one case, the neurologic 
findings were reversible. 
Post-transplant Iymphoproliferative disease (PTLD) is an 
th.t. 
abnormality of lymphocyte proliferation in '*' setting of an 
immunosuppressed patient. The spectrum of PTLD can range from a benign 
lymphoid proliferation) such as a mononucleosis syndrome) to a frankly 
malignant lymphoid tumor. 
immunosuppressive therapy, 
PTLD has been associated with all types of 
Cs.A 
The incidence of PTLD in the syslsGf)sriRe era 
is generally estimated between 2% and 4%. The median time following 
transplantation to the development of PTLD is 6 months, while the 
majority of these tumors occur within 12 months following 
transplantation. 
The cumulative incidence of patients developing dJt n oyo PTLD 
lesions while on FK506 therapy is approximately 2%. All at the cases of 
PTLD occurred within the first year following initiation of FK506, with 
the median time from FK506 therapy to onset of disease being 4 months. _. 
FK506 shows no evidence ot.:alJt increasD~-iK the risk of developing or 
succumbing to PTLD, when compared to other immunosuppressive 
regimens. No patients treated with FK506 for non-transmlan~ 
indications have developed any malignancies. 
(CMV) 
CytomegalOvirUS! infections are considered 
opportunistic infection in the transplant patient. 
the most common 
Several factors 
determine the severity and development of CMV infections. -:t:i:Fe 
Seronegativity and ~f:se of intensive immunosuppression are considered 
major contributing factors. The incidence of CMV infections in the FK506 
treated transplant patients is 20%. This figure is similar to that seen in 
C~A· 
transplanted patients on o1'elesraeril'1e. No patients treated with FK506 for 
non-transplant indications have developed CMV infections. 
Because FK506 is an investigational drug, all of the side 
effects/risks .;!:-thiS drug are as.l' yet. unknown. In particular. the effect 
of FK506 on fertility and on/?-fetus is not known. Of the 12 female 
patients treated with FK506 who became pregnant, there were 2 fetal 
losses, one from CMV infection and the other from premature delivery (24 
weeks). The 10 other babies are healthy and without birth defects. 
Combinations at immunosuppressive agents. including agents acting 
on different aspects of the /tferent or )tterent immune limbs, may 
minimize the side effects of any particular agent. Current and future 
trials using conventional or other experimental agents along with FK506 
may allow further refinement and individualization of immunosuppressive 
regImens. 
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FIGURE LEGEND 
FIGURE 1: Kaplan Meier estimate of patient survival following adult 
cardiac transplantation under FK506 immunosuppression. 
Table 1: Patient Characteristics and Results of 
FK506 vs. Cyclosporine Randomization for Primary 
Liver Transplantation 
Parameter FK506 C~closeorine 
TQlal !"QS 55! 
Number o~ P4.'IUt, 78 76 40 36 
Age EMedy~F lt4n) 43 42 
Diagnosis 
Biliary Cirrhosis 13 16 
Hepatocellular 65 60 
Median FlU (d) 611 594 700 402 
Deaths 7 9 7 2 
Retransplants 7 1 1 8 3 
Rejection-Free 
Actual (current) 34 7 2 5 
One month after 39 16 7 9 
Switch 1 53 32 21 
Steroid -Free 32 1 
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Table 2: Patient Characteristics and Results of 
FK506 vs. Cyclosporine for Primary 
Kidney Transplantation 
Parameter FK506 Cyclosporine 
Number of ~t"tl 
Age E~ttclyaKsyKF 1e~F 
Previous Transplant 
PRA >400/0 
Living Related 
1 yr. Patient Survival 
1 yr. Graft Survival 
Creatinine (mg/dl) 
Freedom from Steroids 
Freedom from Hypertension 
·p<O.05 
234 
41 
76 (320/0) 
41 (17%) 
12 (5%) 
90% 
74% 
2.1 
44% 
43% 
PRA :: r~"~~ tutKK·h~ ~lbo~r 
191 
38 
38 (19%) -
26 (130/0) 
28 (14%) 
94% 
n% 
1.9 
0%-
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